CPC-201

DRUG3 trials

Sponsors

Chase Pharmaceuticals Corporation, an affiliate of Allergan plc

Conditions

Alzheimer's DiseaseDementia of the Alzheimer's Type

Phase 2

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

CompletedNCT02185053

Chase Pharmaceuticals Corporation, an affiliate of Allergan plcAlzheimer's Disease

Start: 2014-07-31End: 2016-07-31Updated: 2020-06-04

Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

CompletedNCT02434666

Chase Pharmaceuticals Corporation, an affiliate of Allergan plcDementia of the Alzheimer's Type

Start: 2015-01-08End: 2016-11-22Updated: 2017-09-20

CPC-201 Alzheimer's Disease Type Dementia: PET Study

WithdrawnNCT02860065

Chase Pharmaceuticals Corporation, an affiliate of Allergan plcAlzheimer's Disease

Start: 2016-09-30End: 2017-06-30Updated: 2017-08-09